Lipid signaling in neural plasticity, brain repair, and neuroprotection

Molecular Neurobiology

Volumn 32, Issue 1, 2005, Pages 89-103

  Bazan, Nicolas G ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cyclooxygenases; Diacylglycerol kinase ; Docosahexaenoic acid; Docosanoids; Neuroprotection; Platelet activating factor; Prostaglandins

Indexed keywords

ARACHIDONIC ACID; AUTACOID; DIACYLGLYCEROL DERIVATIVE; DIACYLGLYCEROL KINASE; DNA; DOCOSAHEXAENOIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPID; MEMBRANE PHOSPHOLIPID; NEUROTOXIN; PHOSPHOLIPASE; PHOSPHOLIPID; POLYUNSATURATED FATTY ACID; PROSTAGLANDIN; PROSTAGLANDIN E2; PROSTAGLANDIN H2; PROSTAGLANDIN SYNTHASE; PROTEIN BAD; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; THROMBOCYTE ACTIVATING FACTOR;

ALZHEIMER DISEASE; BRAIN; BRAIN ISCHEMIA; CELL; CELL FUNCTION; CELL INFILTRATION; CELL MEMBRANE; CELL SURVIVAL; DNA DAMAGE; ENZYME ACTIVITY; ENZYME SYNTHESIS; GENE EXPRESSION; HUMAN; INJURY; LABORATORY; LEUKOCYTE; NERVE CELL; NERVE CELL MEMBRANE; NERVE CELL PLASTICITY; NERVOUS SYSTEM; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PEROXIDATION; PIGMENT EPITHELIUM; PROTEIN EXPRESSION; REPERFUSION; RETINA MACULA DEGENERATION; REVIEW; SPINAL CORD INJURY; STROKE; UPREGULATION;

EID: 23444444518     PISSN: 08937648     EISSN: None     Source Type: Journal    
DOI: 10.1385/mn:32:1:089     Document Type: Review

References (99)

1. Shimizu T. and Wolfe L. S. (1990). Arachidonic acid cascade and signal transduction. J. Neurochem. 55, 1-15.
2. Bazan N. G. (2003). Synaptic lipid signaling: significance of polyunsaturated fatty acids and platelet-activating factor. J. Lipid Res. 44, 2221-2233.
3. Bazan N. G., Packard M. G., Teather L., and Allan G. (1997). Bioactive lipids in excitatory neurotransmission and neuronal plasticity. Neurochem. Int. 30, 225-231.
4. Thoren S., Weinander R., Saha S., et al. (2003). Human microsomal prostaglandin E synthase-1: purification, functional characterization, and projection structure determination. J. Biol. Chem. 278, 22,199-22,209.
5. Kobayashi T., Nakatani Y., Tanioka T., et al. (2004). Regulation of cytosolic prostaglandin E synthase by phosphorylation. Biochem. J. 381, 59-69.
6. Birkle D. L. and Bazan, N. G. (1987). Effect of bicuculline-induced status epilepticus on prostaglandins and hydroxyeicosatetraenoic acids in rat brain subcellular fractions J. Neurochem. 48, 1768-1778.
7. Bazan, N. G. (1995). Inflammation. A signal terminator. Nature 374, 501-502.
8. Packard M. G., Teather L., and Bazan N. G. (1996). Effects of intrastriatal injections of platelet-activating factor and the PAF antagonist BN 52021 on memory. Neurobiol. Learn. Mem. 66, 176-182.
9. Kumar R., Harvey K., Kester M., Hanahan D., and Olsen M. (1988). Production and effects of platelet-activating factor in the rat brain. Biochim. Biophys. Acta. 963, 375-390.
10. Tu B. and Bazan N. G. (2003). Hippocampal kindling epileptogenesis upregulates neuronal cyclooxygenase-2 expression in neocortex. Exper. Neurol. 179, 167-175.
11. Chen C. and Bazan N. G. (2005). Endogenous PGE2 regulates membrane excitability and synaptic transmission in hippocampal CA1 pyramidal neurons. J. Neurophysiol. 93, 929-941.
12. Pettitt T. R. and Wakelam M. J. O. (1999). Diacylglycerol kinase epsilon, but not zeta, selectively removes polyunsaturated diacylglycerol, inducing altered protein kinase C distribution in vivo. J. Biol. Chem. 274, 36,181-36,186.
13. Hodgkin M. N., Pettitt T. R., Martin A., Michell R. H., Pemberton A. J., and Wakelam M. J. (1998).. Diacylglycerols and phosphatidates: which molecular species are intracellular messengers? Trends Biochem. Sci. 23, 200-204.
14. Horrocks L. A. and Farooqui A. A. (1994). NMDA receptor-stimulated release of arachidonic acid: mechanisms for the Bazan effect. In: Cell Signal Transduction, Second Messengers, and Protein Phosphorylation in Health and Disease, Municio A. M. and Miras-Portugal M. T., eds. New York: Plenum Press, pp. 113-128.
15. Sun G. Y., Xu J., Jensen M. D., and Simonyi A. (2004). Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases. J. Lipid Res. 45, 205-213.
16. Aveldaño M. I. and Bazan N. G. (1975). Rapid production of diacylglycerols enriched in arachidonate and stearate during early brain ischemia. J. Neurochem. 25, 919,920.
17. Aveldaño de Caldironi M. I., and Bazan N. G. (1979). Alpha-methyl-p-tyrosine inhibits the production of free arachidonic acid and diacylglycerols in brain after a single electroconvulsive shock. Neurochem. Res. 4, 213-221.
18. Prescott S. M. and Majerus P. W. (1981). The fatty acid composition of phosphatidylinositol from thrombin-stimulated human platelets. J. Biol. Chem. 256, 579-582.
19. Rodriguez de Turco E. B., Tang W., Topham M. K., et al. (2001). Diacylglycerol kinase ε regulates seizure susceptibility and long-term potentiation through arachidonoyl-inositol lipid signaling. Proc. Nat.l Acad. Sci. USA 98, 4740-4745.
20. Petralia R. S., Wang Y. X., Singh S., et al. (1997). A monoclonal antibody shows discrete cellular and subcellular localizations of mGluR1 alpha metabotrophic glutamate receptors. J. Chem. Neuroanat. 13, 77-93.
21. Berthele A., Laurie D. J., Platzer S., Zieglgansberger W., Tolle T. R., and Sommer B. (1998). Differential expression of rat and human type I metabotrophic glutamate receptor splice variant messenger RNAs. Neuroscience 85, 733-749.
22. Lambeau G., Barhanin J., Schweitz H., Qar J., and Lazdunski M. (1989). Identification and properties of very high affinity brain membrane-binding sites for a neurotoxic phospholipase from the taipan venom. J. Biol. Chem. 264, 11,503-11,510.
23. Lambeau G., Schmid-Alliana A., Lazdunski M., and Barhanin J. (1990). Identification and purification of a very high affinity binding protein for toxic phospholipases A2 in skeletal muscle. J. Biol. Chem. 265, 9526-9532.
24. Lambeau G., Ancian P., Barhanin J., and Lazdunski M. (1994). Cloning and expression of a membrane receptor for secretory phospholipases A2. J. Biol. Chem. 269, 1575-1578.
25. Lambeau G., Ancian P., Nicolas J. -P., et al. (1995). Structural elements of secretory phospholipases A2 involved in the binding to M-type receptors. J. Biol. Chem. 270, 5534-5540.
26. Kolko M., DeCoster M. A., Rodriguez de Turco E. B., and Bazan N. G. (1996). Synergy by secretory phospholipase A2 and glutamate on inducing cell death and sustained arachidonic acid metabolic changes in primary cortical neuronal cultures J. Biol. Chem. 271, 32,722, 32,728.
27. 2, platelet-activating factor, and cyclooxygenase-2 in neuronal cells in culture. Neurosci. Lett. 338, 164-168.
28. 2 potentiates glutamate-induced rat striatal neuronal cell death in vivo. Neurosci. Lett. 274, 167-170.
29. 2 potentiates glutamate-induced calcium increase and cell death in primary neuronal cultures. J. Neurosi. Res. 67, 634-645.
30. Matsuzawa A., Makoto M., Atsumi G., et al. (1996). Release of secretory phospholipase A2 from rat neuronal cells and its possible function in the regulation of catecholamine secretion. Biochem. J. 318, 701-709.
31. Scott B. L. and Bazan N. G. (1989). Membrane docosahexanoate is supplied to the developing brain and retina by the liver. Proc. Natl. Acad. Sci. USA 86, 2903-2907.
32. Li J., Wetzel M. G., and O'Brien P. J. (1992). Transport of n-3 fatty acids from the intestine to the retina in rats. J. Lipid Res. 33,539-548.
33. Wang N. and Anderson R. E. (1993). Synthesis of docosahexaenoic acid by retina and retinal pigment epithelium. Biochemistry 32,13,703-13,709.
34. Wang N. and Anderson R. E. (1993). Transport of 22:6n-3 in plasma and uptake into retinal pigment epithelium and retina. Exp. Eye Res. 57, 225-233.
35. Martin R. E., Rodriguez de Turco E. B., and Bazan N. G. (1994). Developmental maturation of hepatic n-3 polyunsaturated fatty acid metabolism: supply of docosahexaenoic acid to retina and brain. J. Nutr. Biochem. 5,151-160.
36. Gordon W. C. and Bazan N. G. (1993). Visualization of [3H]docosahexaenoic acid trafficking through photoreceptors and retinal pigment epithelium by electron microscopic autoradiography. Invest. Ophthalmol. Vis. Sci. 57, 2402-2411.
37. Bazan N. G., Gordon W. C., and Rodriguez de Turco E. B (1992). The uptake, metabolism and conservation of docosahexaenoic acid (22:6 -3). in brain and retina: alterations in liver and retina 22:6 metabolism during inherited progressive retinal degeneration. Am. Oil Chem. Soc. 107-115.
38. Rodriguez de Turco E. B., Jackson F. R., Parkins N., and Gordon W. C. (2000). Strong association of unesterified [3H]docosahexaenoic acid and [3H-docosahexaenoyl]phosphatidate to rhodopsin during in vivo labeling of frog retinal rod outer segments. Neurochem. Res. 25, 695-703.
39. Gordon W. C., Rodriguez de Turco E. B., and Bazan N. B. (1992). Retinal pigment epithelial cells play a central role in the conservation of docosahexaenoic acid by photoreceptor cells after shedding and phagocytosis. Curr. Eye Res. 11, 73-83.
40. Bazan N. G., Rodriguez de Turco E. B., and Gordon W. C (1994). Docosahexaenoic acid supply to the retina and its conservation in photoreceptor cells by active retinal pigment epithelium-mediated recycling. In: Fatty Acids and Lipids: Biological Aspects, Galli C., Simopoulos A. P., and Tremoli E., eds. Basel, Switzerland: Karger, pp. 120-123.
41. Converse C. A., Hammer H. M., Packard C. J., and Shephard J. (1983). Plasma lipid abnormalities in retinitis pigmentosa and related conditions. Trans. Ophthalmol. Soc. UK 103, 508-512.
42. Anderson R. E., Maude M. B., Lewis R. S., Newsome D. A., and Fishman G. A. (1987). Abnormal plasma levels of polyunsaturated fatty acid in autosomal dominant retinitis pigmentosa. Exp. Eye Res. 44, 155-159.
43. Gong J., Rosner B., Rees D. G., Berson E. L., Weigel-Di-Franco C. A., and Schaefer E. J. (1992). Plasma docosahexaenoic acid levels in various genetic forms of retinitis pigmentosa. Invest. Ophthalmol. Vis. Sci. 33, 2596-2602.
44. Hoffman D. R. and Birch D. G. (1998). Omega 3 fatty acid status in patients with retinitis pigmentosa. World Rev. Nutr. Diet 83, 52-60.
45. Bazan N. G. and Rodriguez de Turco E. B. (1996). Alterations in plasma lipoproteins and DHA transport in progressive rod-cone degeneration (prcd). In: Retinal Degeneration and Regeneration, Proceedings of an International Symposium in Kanazawa, Japan, July 8-9, 1995. Kato S., Osborne N. N., and Tamai M., eds. Amsterdam, New York: Kugler Publications, pp. 89-97.
46. Maude M. B., Anderson E. O., and Anderson R. E. (1999). Polyunsaturated fatty acids are lower m blood lipids of Usher's type I but not Usher's type II. Invest. Ophthalmol. Vis. Sci. 39, 2164-2166.
47. Anderson R. E., Maude M. B., Alvarez R. A., Acland G., and Aguirre G. D. (1999). A hypothesis to explain the reduced blood levels of docosahexaenoic acid in inherited retinal degenerations caused by mutations in genes encoding retina-specific proteins. Lipids 34, S235-S237.
48. Aguirre G. D., Acland G. M., Maude M. B., and Anderson R. E. (1997). Diets enriched in docosahexaenoic acid fail to correct progressive rod-cone degeneration (prcd). phenotype. Invest. Ophthalmol. Vis. Sci. 38, 2387-2407.
49. Chen H., Ray J., Scarpino V., Acland G. M., Aguirre G. D., and Anderson R. E. (1999). Synthesis and release of docosahexaenoic acid by the RPE cells of prcd-affected dogs. Invest. Ophthalmol Vis. Sci. 40, 2418-2422.
50. Nourooz-Zadeh J., Liu E. H. C., Anggard E. E., and Halliwell B. (1998). F4-isoprostanes: a novel class of prostanoids formed during peroxidation of docosahexaenoic acid. Biochem. Biophys. Res. Commun. 242, 338-344.
51. Roberts L. J. II, Montine T. J., Markesbery W. R., et al. (1998). Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosahexaenoic acid. J. Biol. Chem. 273, 13,605-13,612
52. Morrow J. D., Hill K. E., Burk R. F., et al. (1990). A series of prostaglandin F2-like compounds are produced in vivo in human by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc. Natl. Acad. Sci.USA 87, 9383-9387.
53. Nourooz-Zadeh J., Liu E. H. C., Yhlen B., Anggard E. E., and Halliwell B. (1999). F4-isoprostanes as specific marker of docosahexaenoic acid peroxidation in Alzheimer's disease. J. Neurochem. 72, 734-740.
54. Bazan N. G., Birkle D. L., and Reddy T. S. (1984). Docosahexaenoic acid (22:6, n 3) is metabolized to lipoxygenase reaction products in the retina. Biochem. Biophys. Res. Commun. 125, 741-747.
55. Bazan N. G. (1990). Supply of n-3 polyunsaturated fatty acids and their significance in the central nervous system. In: Nutrition and the Brain, Wurtman R. J. and Wurtman J. J., eds., New York: Raven Press, pps. 1-24.
56. Marcheselli V. L., Hong S., Lukiw W. J., et al. (2003). Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J. Biol. Chem. 278, 43,807-43,817.
57. Serhan C. N., Hong S., Gronert K., Colgan S. P., Devchand P. R., and Mirick G. (2002). Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J. Exp. Med. 196, 1025-1037.
58. Serhan C. N., Clish C. B., Brannon J., Colgan S. P., Chiang N., and Gronert K. (2000). Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2: nonsteroidal antiinflammatory drugs and transcellular processing. J. Exp. Med. 192, 1197-1204.
59. Hong S., Gronert K., Devchand P. R., Moussignac R. L., and Serhan C. N. (2003). Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. J. Biol. Chem. 278, 14,677-14,687.
60. Kato K., Clark G. D., Bazan N. G., and Zorumski C. F. (1994). Platelet activating factor as a potential retrograde messenger in Ca1 hippocampal long-term potentiation. Nature 367, 175-179.
61. Arai A. and Lynch G. (1992). Antagonists of the platelet-activating factor receptor block long-term potentiation in hippocampal slices. Eur. J. Neurosci. 4, 411-419.
62. Clark G. D., Happel L. T., Zorumski C. F., and Bazan N. G. (1992). Enhancement of hippocampal excitatory synaptic transmission by platelet-activating factor. Neuron 9, 1211-1216.
63. Wieraszko A., Li G., Kornecki E., Hogan M. V., and Ehrlich Y. H. (1993). Long-term potential in the hippocampus induced by platelet-activating factor. Neuron 10, 553-557.
64. Bito H., Nakamura M., Honda Z., et al. (1992). Platelet-activating factor (PAF) receptor in rat brain: PAF mobilizes intracellular Ca2+ in hippocampal neurons. Neuron 9, 285-294.
65. Arai H., Koizumi H., Aoki J., and Inoue K. (2002). Platelet-activating factor acetylhydrolase (PAF-AH). J. Biochem. (Tokyo). 131, 635-640.
66. Bazan N. G. and Allan G. (1988). Platelet-activating factor and other bioactive lipids. In: Cerebrovascular Disease, Pathophysiology, Diagnosis and Management, Ginsberg M. D. and Bogousslavsky J., eds. Malden, MA: Blackwell Science Publishers, pp. 532-555.
67. Bussolino P., Gremo F., Tetta C., Pescarmona G., and Camussi G. (1986). Production of platelet-activating factor by chick retina. J. Biol. Chem. 261, 16,502-16,508.
68. Bussolino F., Torelli S., Stefanini E., and Gremo, F. (1989). Platelet-activating factor production occurs through stimulation of cholinergic and dopaminergic receptors in the chick retina. J. Lipid Med. 1, 283-288.
69. Kornecki E. and Ehrlich Y. H. (1988). Neuoregulatory and neuropathological actions of the ether-phospholipid platelet-activating factor. Science 240, 1792-1794.
70. Prescott S. M., Zimmerman G. A., Stafforini D. M., and McIntyre T. M. (2000). Platelet-activating factor and related lipid mediators. Annu. Rev. Biochem. 69, 419-445.
71. Williams J. H., Errington M. L., Lynch M. A., and Bliss T. V. P. (1989). Arachidonic acid induces a long-term activity-dependent enhancement of synaptic transmission in the hippocampus. Nature 341, 739-742.
72. O'Dell T. J., Hawkins R. D., Kandel E. R., and Arancio O. (1991). Tests of the roles of two diffusible substances in long-term potentiation: evidence for nitric oxide as a possible early retrograde messenger. Proc. Natl. Acad. Sci. USA 88, 11,285-11,289.
73. Kato K., Uruno K., Saito K., and Kato H. (1991). Both arachidonic acid and 1-oleoyl-2-acetyl glycerol in low magnesium solution induce long-term potentiation in hippocampal CA1 neurons in vitro. Brain Res. 563, 94-100.
74. Izquierdo I., Fin C., Schmitz P. K., et al. (1995). Memory enhancement by intrahippocampal, intraamygdala, or intraentorhinal in fusion of platelet-activating factor measured in an inhibitory avoidance task. Proc. Natl. Acad. Sci. USA 92, 5047-5051.
75. Jerusalinsky D., Fin C., Quillfelot J. A., et al. (1994). Effects of antagonists of platelet-activating factor receptors on memory of inhibitory avoidance in rats. Behav. Neural Biol. 62, 1-3.
76. Bazan N. G., Packard M. G., Teather L., and Allan G. (1997). Bioactive lipids in excitatory neurotransmission and neuronal plasticity. Neurochem. Int. 30, 225-231.
77. Teather L. A., Packard M. G., and Bazan N. G. (1998). Effects of posttraining intrahippocampal injections of platelet-activating factor and PAF antagonists on memory. Neurobiol. Learning Memory 70, 349-363.
78. Teather L. A., Packard M. G., and Bazan N. G. (2001). Differential interaction of platelet-activating factor and NMDA receptor function in hippocampal and dorsal striatal memory processes. Neurobiol. Learn Memory 75, 310-324.
79. Chen C. and Bazan N. G. (1999). Platelet-activating factor inhibits ionotropic GABA receptor activity in cultured hippocampal neurons. NeuroReport 10, 3831-3835.
80. Panetta T., Marcheselli V. L., Braquet P., Spinnewyn B., and Bazan N. G. (1987). Effects of a platelet-activating factor antagonist (BN 52021). on free fatty acids, diacylglycerols, polyphosphoinositides and blood now in the gerbil brain: inhibition of ischemia reperfusion induced cerebral injury. Biochem. Biophys. Res. Commun. 149, 580-587.
81. Marcheselli V. L., Rossowska M. J., Domingo M. T., Braquet P., and Bazan N. G. (1990). Distinct platelet-activating factor binding sites in synaptic endings and in intracellular membranes of rat cerebral cortex. J. Biol. Chem. 265, 9140-9145.
82. Squinto S. P., Block A. L., Braquet P., and Bazan N. G. (1989). Platelet-activating factor stimulates a Fos/Jun/AP-1 transcriptional signaling systern in human neuroblastoma cells. J. Neurosci. Res. 24, 558-566.
83. Squinto S. P., Braquet P., Block A. L., and Bazan N. G. (1990). Platelet-activating factor activates HIV promoter in transfected SH-SY5Y neuroblastoma cells and MOLT-4 T lymphocytes. J. Mol. Neurosci. 2, 79-84.
84. Bazan N. G., Squinto S. P., Braquet P., Panetta T., and Marcheselli V. L. (1991). Platelet-activating factor and polyunsaturated fatty acids in cerebral ischemia or convulsions: intracellular PAF-binding sites and activation of a Fos/Jun/AP-1 transcriptional signaling system. Lipids 26, 1236-1242.
85. Honda Z., Nakamura M., Miki I., et al. (1991). Cloning by functional expression of platelet-activating factor receptor from guinea-pig lung. Nature 349, 342-346.
86. Kunz D., Gerard N. P., and Gerard C. (1992). The human leukocyte platelet-activating factor receptor. CDNA cloning, cell surface expression, and construction of a novel epitope-bearing analog. J. Biol. Chem. 267, 9101-9106.
87. Sugimoto T., Tsuchimochi H., McGregor C. G., Mutoh H., Shimizu T., and Kurachi Y. (1992). Molecular cloning and characterization of the platelet-activating factor receptor gene expressed in the human heart. Biochem. Biophys. Res Commun. 189, 617-624.
88. Chen C., Magee J. C., Marcheselli V. L., Hardy M., and Bazan N. G. (2001). Attenuated long-term potentiation in hippocampal dentate gyrus neurons of mice deficient in the platelet-activating factor receptor. J. Neurophysiol. 85, 384-390.
89. Kobayashi K., Ishii S., Kume K., Takahasi T., Shimizu T., and Manabe T. (1999). Platelet-activating factor receptor is not required for long-term potentiation in the hippocampal CA1 region. Eur. J. Neurosci. 11, 1313-1316.
90. Ihida K., Predescu D., Czekay R. -P., and Palade G. E. (1999). Platelet activating factor receptor (PAF-R). is found in a large endosomal compartment in human umbilical vein endothelial cells. J.Cell Sci. 112, 285-295.
91. Marrache A. M., Gobeil F. Jr., Bernier S. G., et al. (2002). Proinflammatory gene induction by platelet-activating factor mediated via its cognate nuclear receptor. J. Immunol. 169, 6474-6481.
92. Bazan N. G., Fletcher B. S., Herschman H. R., and Mukherjee P. K. (1994). Platelet-activating factor and retinoic acid synergistically activate the inducible prostaglandin synthase gene. Proc. Natl. Acad. Sci. USA 91, 5252-5256.
93. Prehn J. H. M. and Krieglstein J. (1993). Platelet-activating factor antagonists reduce excitotoxic damage in cultured neurons from embryonic chick telencephalon and protect the rat hippocampus and neocortex from ischemic injury in vivo. J. Neurosci. Res. 34, 179-188.
94. Gilboe D. D., Kintner D., Fitzpatrick J. H., et al. (1991). Recovery of postischemic brain metabolism and function following treatment with a free radical scavenger and platelet-activating factor antagonists. J. Neurochem. 56, 311-319.
95. Lindsberg P. J., Yue T. -L., Frerichs K. U., Hallenbeck J. M., and Feuerstein G. (1990). Evidence for platelet-activating factor as a novel mediator of experimental stroke in rabbits. Stroke 21, 1452-1457.
96. Oberpichler H., Sauer D., Rossberg C., Mennel H. D., and Krieglstein J. (1990). PAF antagonist ginkgolide-B reduces post-ischemic neuronal damage in rat brain hippocampus. J. Cereb.Blood Flow Metab. 10, 133-135.
97. Kochanek P. M., Dutka A. J., Kumaroo K. K., and Hallenbeck J. M. (1987). Platelet-activating factor receptor blockade enhances recovery after multifocal brain ischemia. Life Sci. 41, 2639-2644.
98. Ogden F., DeCoster M. A., and Bazan N. G. (1998). Recombinant plasma-type platelet-activating factor acetylhydrolase attenuates NMDA-induced hippocampal neuronal apoptosis. J. Neurosci. Res. 53, 677-684.
99. Tjoelker L. W., Wilder C., Eberhardt C., et al. (1995). Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature 374, 549-553.